Agios hit a setback for Tibsovo in Europe this year however after the EMA rejected the marketing application for the drug. Servier is paying $1.8 billion upfront for the oncology assets, with the ...

Now, Servier says it has data from a phase 3 trial in the previously-untreated group that could allow it to have another go at European approval, and also support the drug's use as part of a first ...

Servier’s decision to exit a Parkinson’s disease pact has triggered belt tightening at French biotech Oncodesign Precision Medicine. | Servier’s decision to exit a Parkinson’s disease pact has ...

Servier will lead the development activities ... Also Read: Black Diamond Therapeutics’ Lead Drug Candidate Shows Initial Anti-Tumor Activity In Certain Type Of Lung Cancer Resistant To ...

the biotech has licensed the RAF inhibitor to Servier for $70 million upfront and up to $710 million in milestones. In October, Black Diamond concluded its attempt to push two cancer drugs through ...

“Servier’s commitment to innovation and deep ... the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, Eastern Europe ...

Per the terms of the sale agreement between the two companies, Servier made a milestone payment ... contingent on the FDA’s approval for the drug. Management intends to utilize the above funds ...

SURESNES, France and CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics ...